Across TCGA pan-cancer cohorts, KRT16 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated KRT16 data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher KRT16 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KRT16 expression acts as an unfavorable survival marker.

SARC, SKCM, and GBM are the cancer types where KRT16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	OS	Median	All	0.151	0.745	.001	12	view →
SKCM	DFS	Median	III,IV	0.256	0.614	.004	9	view →
GBM	OS	Median	All	0.075	0.416	.011	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: KRT16 tumor-vs-normal RNA expression · all KRT16 data types